# Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

> **NCT02641093** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Trisha Wise-Draper** · enrollment: 96 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **PROCEDURE:** Surgery
- **RADIATION:** Radiation Therapy
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02641093
- **Lead sponsor:** Trisha Wise-Draper
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-01
- **Primary completion:** 2021-04-16
- **Final completion:** 2026-11-02
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641093, "Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02641093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*